Table 1.
Distribution of race/ethnicity, nSES, stage at diagnosis and molecular subtype by newly defined areas for female invasive breast cancer cases diagnosed in San Francisco, 2006–2015
| All | 1. Center-South | 2. Center-West | 3. Center-East | 4. East | 5. Southeast | 6. Southwest | 7. West | 8. North | 9. Northeast | |
|---|---|---|---|---|---|---|---|---|---|---|
| All | 5622 | 511 (9.1%) | 614 (10.9%) | 330 (5.9%) | 348 (6.2%) | 588 (10.5%) | 810 (14.4%) | 871 (15.5%) | 671 (11.9%) | 879 (15.6%) |
| Race/ethnicity | ||||||||||
| NHW | 2,673 (47.5%) | 290 (56.8%) | 424 (69.1%) | 121 (36.7%) | 219 (62.9%) | 116 (19.7%) | 236 (29.1%) | 369 (42.4%) | 519 (77.3%) | 379 (43.1%) |
| B/AA | 404 (7.2%) | 17 (3.3%) | 23 (3.7%) | 15 (4.5%) | 18 (5.2%) | 150 (25.5%) | 57 (7.0%) | 12 (1.4%) | 18 (2.7%) | 94 (10.7%) |
| H/L | 475 (8.4%) | 31 (6.1%) | 41 (6.7%) | 82 (24.8%) | 34 (9.8%) | 80 (13.6%) | 102 (12.6%) | 30 (3.4%) | 28 (4.2%) | 47 (5.3%) |
| AANHPI | 2,043 (36.3%) | 171 (33.5%) | 121 (19.7%) | 110 (33.3%) | 74 (21.3%) | 239 (40.6%) | 411 (50.7%) | 458 (52.6%) | 104 (15.5%) | 355 (40.4%) |
| Other/Unknown | 27 (0.5%) | * | * | * | * | * | * | * | * | * |
| nSES | ||||||||||
| 1 | 1,133 (20.2%) | * | * | 71 (21.5%) | 12 (3.4%) | 381 (64.8%) | 224 (27.7%) | * | * | 445 (50.6%) |
| 2 | 1,224 (21.8%) | * | <5 (0.5%) | 169 (51.2%) | 13 (3.7%) | 122 (20.7%) | 448 (55.3%) | 222 (25.5%) | 12 (1.8%) | 235 (26.7%) |
| 3 | 1,127 (20.0%) | 59 (11.5%) | 81 (13.2%) | 84 (25.5%) | * | 85 (14.5%) | 133 (16.4%) | 481 (55.2%) | 34 (5.1%) | 170 (19.3%) |
| 4 | 1,053 (18.7%) | 234 (45.8%) | 237 (38.6%) | * | 152 (43.7%) | * | 5 (0.6%) | 148 (17.0%) | 261 (38.9%) | 16 (1.8%) |
| 5 | 1,085 (19.3%) | 218 (42.7%) | 293 (47.7%) | 6 (1.8%) | 171 (49.1%) | * | * | 20 (2.3%) | 364 (54.2%) | 13 (1.5%) |
| Age at Diagnosis (m, SD) | 61.07 (14.81) | 63.53 (15.15) | 59.64 (14.78) | 57.87 (15.63) | 56.56 (14.1) | 59.81 (13.99) | 61.2 (13.8) | 61.54 (14.92) | 61.82 (15.37) | 63.32 (14.76) |
| Stage at Diagnosis | ||||||||||
| Stage I-IIa | 4,022 (71.5%) | 382 (74.8%) | 433 (70.5%) | 232 (70.3%) | 254 (73.0%) | 387 (65.8%) | 598 (73.8%) | 632 (72.6%) | 518 (77.2%) | 586 (66.7%) |
| Stage IIb and higher | 1,430 (25.4%) | 116 (22.7%) | 165 (26.9%) | 87 (26.4%) | 88 (25.3%) | 178 (30.3%) | 193 (23.8%) | 210 (24.1%) | 138 (20.6%) | 255 (29.0%) |
| Stage unknown | 170 (3.0%) | 13 (2.5%) | 16 (2.6%) | 11 (3.3%) | 6 (1.7%) | 23 (3.9%) | 19 (2.3%) | 29 (3.3%) | 15 (2.2%) | 38 (4.3%) |
| Molecular Subtype | ||||||||||
| HR+/HER2- | 3,785 (67.3%) | 364 (71.2%) | 438 (71.3%) | 221 (67.0%) | 237 (68.1%) | 381 (64.8%) | 521 (64.3%) | 607 (69.7%) | 474 (70.6%) | 542 (61.7%) |
| HR+/HER2+ | 565 (10.0%) | 40 (7.8%) | 56 (9.1%) | 40 (12.1%) | 37 (10.6%) | 59 (10.0%) | 91 (11.2%) | 73 (8.4%) | 64 (9.5%) | 105 (11.9%) |
| HR-/HER2+ | 296 (5.3%) | 21 (4.1%) | 28 (4.6%) | 15 (4.5%) | 15 (4.3%) | 36 (6.1%) | 43 (5.3%) | 51 (5.9%) | 26 (3.9%) | 61 (6.9%) |
| TNBC | 540 (9.6%) | 42 (8.2%) | 52 (8.5%) | 35 (10.6%) | 43 (12.4%) | 70 (11.9%) | 86 (10.6%) | 81 (9.3%) | 54 (8.0%) | 77 (8.8%) |
| Unclassified | 436 (7.8%) | 44 (8.6%) | 40 (6.5%) | 19 (5.8%) | 16 (4.6%) | 42 (7.1%) | 69 (8.5%) | 59 (6.8%) | 53 (7.9%) | 94 (10.7%) |
*
Suppressed due to n<5